Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021

Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.

[thumbnail of Oncology Fact Sheet Nr.21_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
87kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system
Language:	English
Series Name:	Oncology Fact Sheet Nr. 21
Deposited on:	29 Oct 2020 12:36
Last Modified:	01 Feb 2021 18:29

Repository Staff Only: item control page